SCHEMBL24166155

SCHEMBL24166155

COCCn1cnc2ccc(N)c(-c3ccncc3)c2c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
NFATC1 O95644 1/20 0.38
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
BRAF P15056 1/20 0.38
HSD17B10 Q99714 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
NPC1 O15118 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRK2 P25098 1/20 0.35
MAPT P10636 2/20 0.35
AURKA O14965 1/20 0.35
TTK P33981 1/20 0.35
AURKB Q96GD4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30656856 1.00 KMT2A (0.40) KMT2AMEN1NFATC1GSK3BDYRK1A
SCHEMBL24166503 0.90 ALDH1A1 (0.43) KMT2AMEN1BRAFHSD17B10KDM4E
SCHEMBL30656811 0.90 ALDH1A1 (0.43) KMT2AMEN1BRAFHSD17B10KDM4E
SCHEMBL30656795 0.88 BRAF (0.41) KMT2AMEN1BRAFHSD17B10KDM4E
SCHEMBL24165960 0.88 BRAF (0.41) KMT2AMEN1BRAFHSD17B10KDM4E
SCHEMBL30656834 0.88 ALOX15 (0.46) KMT2AMEN1HSD17B10ALDH1A1NPC1
SCHEMBL24166480 0.88 ALOX15 (0.46) KMT2AMEN1HSD17B10ALDH1A1NPC1
SCHEMBL24166466 0.87 NR3C1 (0.39) KMT2AMEN1BRAFHSD17B10KDM4E
SCHEMBL30656808 0.87 NR3C1 (0.39) KMT2AMEN1BRAFHSD17B10KDM4E
SCHEMBL24166121 0.87 CLK1 (0.43) KMT2AMEN1DYRK1ABRAFHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC KMT2A 3393/4885MEN1 3700/4885NFATC1 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.